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3D-QSARAbstract This investigation analyzes the common chemical features for 15-lipoxygenase (15-LOX)
inhibitors to develop ligand-based pharmacophore models for lipoxygenase inhibitory activity. The
present model is based on a dataset of 47 indolizine derivatives that exhibit inhibition against
15-LOX enzyme isolated from soybeans. Pharmacophore models were developed with pharmaco-
phoric features namely: aromatic ring (R) and hydrogen bond acceptor (A). The pharmacophore
hypothesis ARRR.5 with R2 value 0.9451 yields a 3D-QSAR model which is statistically signiﬁcant
and the best pharmacophore hypothesis. External validation is performed to evaluate the robust-
ness of the model and in this study; it was performed on a test set where correlation coefﬁcient
between experimental and predicted activity values was found to be 0.8508. The study suggested
that pharmacophore modeling approach could be used as a tool for the development of lead
structures.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
15-Lipoxygenase (15-LOX) enzyme is generally found in retic-
ulocytes, eosinophils, macrophages and skin.1 Role of 15-
lipoxygenase in the development of different kinds of ailments
like atherosclerosis, atherogenesis,2–5 prothrombotic,6 prostatecancer,7,8 colorectal cancer9 etc has been evaluated by different
researchers from time to time. In all these studies,2–9 authors
tried to establish the mechanism behind 15-lipoxygenase role
in the development of different diseases. In view of these, it
is relevant to design 15-LOX inhibitors with different hetero-
cyclic moieties viz. indole, indolizine, oxazole, quinoline, iso-
quinoline etc for the treatment of the above mentioned
ailments.10–12 In the lights of these facts, Gundersen and
coworkers13 synthesized different indolizine derivatives for
lipoxygenase inhibitory potential. Table 1 summarizes the
15- LOX inhibitory activity of indolizine derivatives.
Pharmacophore methodology has been used in designing of
new chemical entities as well as in lead optimization and multi-
target drug design. As per the deﬁnition by IUPAC,14 a
Table 1 Inhibitory activity of the indolizine derivatives against 15-LOX enzyme isolated from soybeans.
Ligand name Series R QSAR Set Experimental activity # PLS Factors Predicted activity
3 X –H Training 4.522 1, 2, 3 4.30, 4.48, 4.52
4a X –OCH3 Training 4.481 1, 2, 3 4.50, 4.52, 4.50
4b X –OCH2Ph Training 4.508 1, 2, 3 4.52, 4.53, 4.53
4c X –OCH2–C6H4-p–Cl Training 4.508 1, 2, 3 4.57, 4.47, 4.51
4d X –OCH2–C6H4-p–F Training 4.508 1, 2, 3 4.57, 4.47, 4.51
4e X –OCH2–C6H4-p–CH3 Training 4.431 1, 2, 3 4.57, 4.46, 4.49
4f X –OCH2–C6H4-p–OCH3 Training 4.494 1, 2, 3 4.57, 4.46, 4.50
4g X –OCH2–C6H4-m–Cl Training 4.508 1, 2, 3 4.57, 4.47, 4.51
4h X –OCH2–C6H4-o–OCH3 Training 4.537 1, 2, 3 4.52, 4.55, 4.55
4i X –OCH2OCH2Ph Training 4.568 1, 2, 3 4.54, 4.58, 4.59
4j X –CH2OCH(CH2OCH2Ph)2 Training 4.508 1, 2, 3 4.58, 4.51, 4.50
5a X –OSO2CF3 Training 4.337 1, 2, 3 4.54, 4.46, 4.48
5b X –OTs Training 4.769 1, 2, 3 4.59, 4.54, 4.62
6a X –OCOCH3 Training 4.508 1, 2, 3 4.53, 4.55, 4.51
6b X –OCO–C6H4-p–OCH3 Training 4.552 1, 2, 3 4.56, 4.48, 4.52
6c X –OCO–C6H4-m–OCH3 Training 4.552 1, 2, 3 4.55, 4.53, 4.50
6d X –OCO–C6H4-o–OCH3 Training 4.522 1, 2, 3 4.57, 4.48, 4.52
7a X –CH3 Training 4.568 1, 2, 3 4.33, 4.52, 4.57
7b X –CH2Ph Training 4.568 1, 2, 3 4.32, 4.54, 4.59
7c X –Ph Test 4.552 1, 2, 3 4.33, 4.51, 4.55
7d X –C6H4-p–OCH3 Test 4.619 1, 2, 3 4.35, 4.55, 4.60
7e X –C6H4-m–OCH3 Test 4.698 1, 2, 3 4.35, 4.54, 4.59
7f X –C6H4-o–OCH3 Test 4.698 1, 2, 3 4.35, 4.54, 4.59
7g X –(2-furyl) Test 4.619 1, 2, 3 4.58, 4.60, 4.56
7h X –(2-thienyl) Test 4.619 1, 2, 3 4.33, 4.49, 4.52
7i X –(3-thienyl) Test 4.721 1, 2, 3 4.34, 4.53, 4.58
8a X –CHO Test 4.537 1, 2, 3 4.51, 4.52, 4.54
8b X –COCH3 Test 4.638 1, 2, 3 4.51, 4.55, 4.55
8c X –COPh Test 4.638 1, 2, 3 4.64, 4.68, 4.64
9a X –CH2OH Test 4.585 1, 2, 3 4.55, 4.60, 4.56
9b X –CH(OH)CH3 Test 4.585 1, 2, 3 4.61, 4.64, 4.60
9c X –CH(OH)Ph Test 4.508 1, 2, 3 4.65, 4.70, 4.64
9d X –C(CH3)(OH)Ph Test 4.769 1, 2, 3 4.66, 4.71, 4.68
9e X –CH(OH)cyclohexyl Training 4.638 1, 2, 3 4.66, 4.71, 4.63
9f X –CH(OH)–C6H4-p–Cl Test 4.638 1, 2, 3 4.54, 4.69, 4.64
9g X –CH(OH)–C6H4-p–CH3 Test 4.657 1, 2, 3 4.53, 4.68, 4.64
9h X –CH(OH)–C6H4-p–OCH3 Training 4.769 1, 2, 3 4.56, 4.73, 4.77
10 X –CH(OCH3)Ph Training 4.677 1, 2, 3 4.66, 4.71, 4.66
11a X –OCH3 Test 4.537 1, 2, 3 4.47, 4.42, 4.41
11b X –OCH2CH3 Test 4.552 1, 2, 3 4.42, 4.44, 4.41
11c X –OSO2CF3 Test 4.366 1, 2, 3 4.47, 4.38, 4.40
11d X –OTs Test 4.769 1, 2, 3 4.45, 4.46, 4.70
11e X –OCOCH3 Test 4.494 1, 2, 3 4.47, 4.40, 4.40
12 X
OPh
OCH2 Test 3.889 1, 2, 3 4.24, 4.21, 3.93
13a Y p-OCH3 Training 3.777 1, 2, 3 4.02, 3.87, 3.79
13b Y m-OCH3 Training 4.04 1, 2, 3 4.13, 4.04, 3.98
13c Y o-OCH3 Training 4.07 1, 2, 3 4.12, 4.07, 3.99
64 V. Sharma, V. Kumarpharmacophore model can be deﬁned as ‘an ensemble of steric
and electronic features that is necessary to ensure the optimal
supramolecular interactions with a speciﬁc biological target
and to trigger (or block) its biological response’. In a review
by Yang,15 author described the implications of pharmaco-
phore modeling in drug discovery while Cruz and co-workers
reviewed the ﬁnding of 3D-QSAR studies on single site poly-
merization catalysts.16
In the present study, PHASE module of Schro¨dinger suite
was used to develop 3D-QSAR models on aligning pharmaco-
phore points.17 The developed hypothesis mainly identiﬁes themost signiﬁcant structural properties required to judge lipoxy-
genase inhibitory activity of the indolizine ring.2. Experimental
2.1. Dataset
To design a pharmacophore model, a set of 47 indolizine
derivatives with potent lipoxygenase inhibitory activity was
used to develop this pharmacophore model.13 Indolizine
NCN
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O
O
R
X; R = alkyl/aryl groups Y; R = methoxy
Figure 1 Basic structures of indolizine derivatives.
Table 2 Parameters of four featured pharmacophore
hypothesis.
Sr.
No.
Hypothesis Survival
score
Factor R2 Pearson-
R
1 ARRR.5 3.094 1, 2, 3 0.6343; 0.889;
0.9451
0.7439
2 RRRR.20 3.669 1, 2, 3 0.5004;
0.6812; 0.8735
0.4026
3 RRRR.17 3.669 1, 2, 3 0.5004;
0.6812; 0.8735
0.4026
4 RRRR.18 3.613 1, 2, 3 0.5043;
0.6964; 0.8751
0.6301
5 RRRR.21 3.613 1, 2, 3 0.5043;
0.6964; 0.8751
0.6301
6 RRRR.8 3.482 1, 2, 3 0.5132;
0.6719; 0.8605
0.5831
7 RRRR.4 3.482 1, 2, 3 0.5132;
0.6719; 0.8605
0.5831
8 RRRR.3 3.452 1, 2, 3 0.512; 0.696;
0.8725
0.5844
9 RRRR.23 3.000 1, 2, 3 0.4936; 0.694;
0.8311
0.3394
10 RRRR.19 2.852 1, 2, 3 0.5144;
0.6941; 0.8649
0.5205
Figure 2 (A) PHASE generated pharmacophore model ARRR.5 ill
(R4; R5; R8; orange) features. (B) All ligands overlapped on the gene
Pharmacophore model on indolizine derivatives 65derivatives were screened for their inhibitory activity against
15-lipoxygenases from soybeans and rabbit reticulocytes but
due to insufﬁcient data, dataset of 15-lipoxygenases from soy-
beans was selected for 3D-QSAR study. For ease in cal-
culation, standard deviation for each value was omitted from
the chosen dataset. The IC50 value of each compound was con-
verted into pIC50 (negative logarithm of IC50). The selected
dataset was randomly divided into test (22) and training set
(25). Basic structure and their respective substituents used in
the study are shown in Fig. 1 and Table 1, respectively along
with their experimental/predicted activity.
2.2. Pharmacophore modeling
For the generation of pharmacophore models, PHASE soft-
ware was used. Maestro algorithm was used to draw the
chemical structures of the molecules followed by the applica-
tion of LigPrep program to produce perfectly chiral and high
quality all-atom 3D structures. The structures so obtained
were subjected to ionization at pH 7. Conformers of the train-
ing set molecules were generated with the Monte Carlo method
by OPLS-2005 force ﬁeld as provided in MacroModel 9.6
2008, then these were minimized using Truncated Newton
Conjugate Gradient.18,19
Pharmacophoric features viz. aromatic ring (R) and hydro-
gen bond acceptor (A) were used to generate pharmacophore
sites to map all essential chemical features of dataset mole-
cules. Three to six sites were ﬁxed for all the features.
Pharmacophore hypotheses and common pharmacophore
were created by PHASE, 2008. The regression was carried
out on hypotheses with stepwise increasing number of PLS fac-
tors. 3D-QSAR models were generated using 25 molecules of
training set with 1–3 PLS factors and by ﬁxing grid spacing
of 1 A˚. Further, common pharmacophore hypotheses wereustrating hydrogen bond acceptor (A2; pink), and aromatic rings
rated model ARRR.5.
66 V. Sharma, V. Kumarevaluated using survival score to ﬁnd the best alignment of the
active molecules using root mean square deviation value of
1.2 A˚. The scoring of hypotheses were performed using default
parameters. Survival score secured by each hypothesis, is the
measure of the quality of alignment for a particular hypothe-
ses. The stepwise detailed methodology has already been
explained.20
2.3. Validation of pharmacophore model
For the assessment of the best hypotheses, validation needs to
be performed wherein the pharmacophore model can be vali-
dated for its ability to accurately predict the biological activity
or for the identiﬁcation of the active molecules from the data-
set. Among the above two options; the activity prediction ofTable 3 Distances between different sites of model ARRR.5.
Entry Site1 Site2 Distance
ARRR.5 A2 R8 4.202
ARRR.5 A2 R4 3.417
ARRR.5 A2 R5 7.277
ARRR.5 R8 R4 2.153
ARRR.5 R8 R5 5.087
ARRR.5 R4 R5 4.072
Table 4 Angles between different sites of model ARRR.5.
Entry Site1 Site2 Site3 Angle
ARRR.5 R8 A2 R4 30.7
ARRR.5 R8 A2 R5 43
ARRR.5 R4 A2 R5 15
ARRR.5 A2 R8 R4 54.1
ARRR.5 A2 R8 R5 102.7
ARRR.5 R4 R8 R5 50.5
ARRR.5 A2 R4 R8 95.3
ARRR.5 A2 R4 R5 152.5
ARRR.5 R8 R4 R5 105.4
ARRR.5 A2 R5 R8 34.3
ARRR.5 A2 R5 R4 12.5
ARRR.5 R8 R5 R4 24.1
Table 5 Fitness score of test and training set molecules based on h
Ligand name Fitness score Ligand name Fitness score
3 1.51 5b 2.13
4a 1.92 6a 2.08
4b 1.84 6b 2.13
4c 2.12 6c 2
4d 2.12 6d 2.13
4e 2.12 7a 1.53
4f 2.11 7b 1.26
4g 2.12 7c 1.33
4h 1.85 7d 1.51
4i 1.82 7e 1.51
4j 2.06 7f 1.51
5a 2.18 7g 2.54test set was chosen as the validation criteria for the developed
pharmacophore model. Brieﬂy, the test molecules were pro-
cessed using the same development protocol as was used for
the training set molecules followed by activity prediction of
test molecules employing the pharmacophore model developed
in the study. Finally, determination of a prospective cor-
relation between experimental and predicted activities of the
test molecules was envisaged.
3. Results and discussion
Indolizine derivatives are well known for their biological
potential viz. antiproliferative, anti-inﬂammatory, antitu-
bercular, antimicrobial as reviewed by Sharma and Kumar.10
Ligand-based drug design is an important tool by which a
pharmacophore model may be developed that can deﬁne mini-
mum structural requirements essential for molecule-target
binding.
The pharmacophore model was developed by using twenty-
ﬁve molecules wherein hydrogen bond acceptor (A) and aro-
matic rings (R) were employed as pharmacophore features
for creating interaction sites. Pharmacophore hypotheses with
four features were generated and were evaluated for stringent
scoring function analysis. Table 2 depicts the results of four
featured pharmacophore hypotheses. ARRR.5 represented
the best hypothesis (Fig. 2) with highest R2 value of 0.9451,
highest Pearson R value of 0.7439 and survival score of
3.094, featuring a hydrogen bond acceptor (A) and aromatic
rings (R). Tables 3 and 4 represent the distances and angles
respectively between different ARRR.5 sites.
The ﬁtness score for the ligands was calculated by
superimposing each ligand on ARRR.5 (Table 5). The ﬁtness
score could be helpful in judging the suitability of a model
as it measures the distance between the feature and the center
of the hypothesis feature while on the other hand, it also evalu-
ates if the feature is mapped or not.21
The validity of generated pharmacophore model was car-
ried out by performing the activity prediction of training set
in addition to the survival score analysis. Therefore, the
ARRR.5 model was regressed against the training set.
Predicted and experimental 15-LOX inhibitory activities of
training set molecules based on ARRR.5 hypothesis are shown
in Table 1. The predicted activities of training set illustrated aypothesis ARRR.5.
Ligand name Fitness score Ligand name Fitness score
7h 1.34 9h 2.18
7i 1.53 10 2.44
8a 2.12 11a 2.2
8b 2.24 11b 1.87
8c 2.61 11c 2.16
9a 2.17 11d 1.74
9b 2.83 11e 2.22
9c 3 12 1.38
9d 2.34 13a 0.87
9e 2.68 13b 1.33
9f 1.79 13c 1.28
9g 1.77
Figure 3 Relationship between experimental and predicted 15-LOX inhibitory activity of training set (A) and test set (B) molecules.
Pharmacophore model on indolizine derivatives 67correlation of 0.9451 with reported 15-lipoxygenase inhibitory
activity using the ARRR.5 model (Fig. 3A).
The validity and predictive character of ARRR.5 was done
by prediction proﬁling of the test set with 22 molecules.
Similar to training set; the test set was orderly built and mini-
mized before carrying out the conformational analysis.
Subsequently, biological activities of the test set were predicted
with the help of ARRR.5 model and furthermore compared
with the experimental 15-LOX inhibitory activity.
Table 1 corresponds to the predicted and experimental
activity (pIC50) values of the test as well as training set mole-
cules with a close correlation value of 0.8508 for test set mole-
cules (Fig. 3B). Goyal and co-workers proposed that a reliable
model can be duly constructed if squared predictive correlation
coefﬁcient is more than 0.60.22 In accordance with this obser-
vation; the ARRR.5 model could be used for the prediction of
15-LOX inhibitory activity.4. Conclusion
In this study, ARRR.5 pharmacophore model was created
using indolizine derivatives acting as 15-LOX inhibitors.
Hypothesis ARRR.5 might be considered as the best pharma-
cophore model as it displayed a good regression coefﬁcient
value of 0.9451, Pearson R 0.7439 and survival score 3.094.
It consisted of three aromatic rings (R) and one hydrogen
bond acceptor (A). A good correlation between experimental
and predicted activity of the training (R2 = 0.9473) and test
(R2 = 0.8508) set molecules was displayed by ARRR.5 model.
In accordance with the above results, 15-LOX inhibitory
activity was precisely predicted by ARRR.5 model.
Validation further supports the appropriateness of ARRR.5
model. At last, it might be concluded that ARRR.5
model could be an appropriate tool for the designing of new
15-LOX inhibitors.5. Conﬂict of interest
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